IL-13 receptor alpha 2 inhibitors (Pfizer)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIL-13 receptor alpha 2 inhibitors (Pfizer)
Drug Alias NamehAB08-MTI1hAB08-MTI2hAB08 conjugated to microtubule inhibitor 1/2 (Pfizer)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 inhibitors
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A